Physician profile
Ira Gore
NPI 1447275565
$3,408.29
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,900 · 2020: $641 · 2021: $803 · 2022: $42.64 · 2023: $21.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $506.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $405.27 | 2019-2022 | |
| Janssen Biotech, INC. | $381.25 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.01 | 2019-2020 | |
| Amgen INC. | $215.51 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $188.31 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $160.88 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $148.40 | 2019-2023 | Epkinly |
| Tesaro, INC. | $146.84 | 2019 | |
| Seagen INC. | $98.37 | 2019-2021 | |
| Genentech USA, INC. | $81.48 | 2019 | |
| Exelixis INC. | $78.73 | 2019 | |
| Lilly USA, LLC | $75.32 | 2019-2020 | |
| Celgene Corporation | $70.43 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $60.05 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $54.07 | 2019-2021 | |
| Pfizer INC. | $53.44 | 2019-2020 | |
| Astellas Pharma US INC | $52.01 | 2019-2020 | |
| Epizyme, INC. | $40.02 | 2021 | |
| Karyopharm Therapeutics INC. | $30.82 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.34 | 2019 | |
| Rigel Pharmaceuticals, INC. | $24.09 | 2019 | |
| Pharmacosmos Therapeutics INC. | $23.84 | 2021 | |
| Aurobindo Pharma USA, INC. | $16.79 | 2020 | |
| Dova Pharmaceuticals | $16.26 | 2019 | |
| Kite Pharma, INC. | $14.87 | 2021 | |
| Glaxosmithkline, LLC. | $14.72 | 2021 | |
| Daiichi Sankyo INC. | $14.21 | 2021 | |
| Beigene USA, INC. | $12.67 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.41 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Secura Bio, INC. | $11.53 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.